Skip to content
Back
  • Home
  • About us
    • Company focus
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
    • R&D Focus
    • R&D Levers
  • Pipeline
    • Pipeline
    • JM-010
    • CP-012
    • Discovery
  • News
    • Press releases
    • Upcoming events
  • Contact
    • Business Development
    • Social network
Two men talking

Scientific
advisory board

Discover our board

 

René Holm, PhD
Professor, University of Southern Denmark

Dr. René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined H. Lundbeck A/S in 2001 and then moved to Janssen in 2016, where he headed drug product development for parenteral and liquid formulations. Dr. Holm has worked within pharmaceutical development and the associated process development, developability in drug discovery, physical chemistry and material science covering both small and large molecules and have been deeply involved in several INDs with advantaged drug delivery. As of 2021 Dr. Holm has been a full professor in Pharmaceutical physical chemistry at the university of Southern Denmark.
Dr. Holm is (co-) author of more than 240 original articles in peer-reviewed journals and patents in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and is an honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark

 

Mikael Thomsen, PhD
Co-Founder, expert drug developer, seasoned biotech entrepreneur

Dr. Mikael Thomsen has more than 25 years of experience from the pharma and biotech industry and worked within different major pharmaceutical companies including Novartis Pharma, Switzerland, Novo Nordisk, Denmark as well as at the U.S. Food and Drug Administration. He is co-founder of numerous international biotech companies including Contera Pharma. He is an experienced Clinical Pharmacologist and has had roles as Head of Clinical Pharmacology, VP Development, Chief Development Officer and Chief Scientific Officer, where he managed departments organizing all the activities leading a drug from late Discovery trough clinical development. He has been involved in several product filings as well as interactions with authorities from EMA, FDA and MHLW (Japan).

Mikael Thomsen has two M. Sc. degrees (Pharmacy and Human Biology; from University of Pharmaceutical Sciences, Copenhagen and University of Copenhagen, Medical Faculty) and has a PhD in Pharmacology and Toxicology (University of Copenhagen and FDA site, Arkansas, US) and a degree in Pharmaceutical Medicine (ECPM, Basel, Switzerland). He is a member of several pharmaceutical societies and has authored or co-authored more than 50 publications/abstracts related to drug development as well co-author of several patents.

Seong-Beom Koh, MD, PhD
Professor, Korea University, Seoul, South-Korea

Professor Seong-Beom Koh, MD, PhD, is a neurologist at Korea University | KU, Department of Neurology, in Seoul. He has contributed significantly to the field of movement disorders, with special focus on Parkinson´s disease, and has authored or co-authored more than 150 publications.

January 2022 ~ today: 9th President of The Korean Movement Disorder Society
September 2006 – August 2007: Research Associate of MRC Clinical Sciences Centre, London, United Kingdom
March 2003 ~ today: Director neurology Korea University Guro Hospital, Seoul, South-Korea
March 2001 – today: Professor (Full), Department of Neurology, Korea University, Seoul, South-Korea

René Holm, PhD
Professor, University of Southern Denmark

Dr. René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined H. Lundbeck A/S in 2001 and then moved to Janssen in 2016, where he headed drug product development for parenteral and liquid formulations. Dr. Holm has worked within pharmaceutical development and the associated process development, developability in drug discovery, physical chemistry and material science covering both small and large molecules and have been deeply involved in several INDs with advantaged drug delivery. As of 2021 Dr. Holm have been a full professor in Pharmaceutical physical chemistry at the university of Southern Denmark.

Dr. Holm is (co-) author of more than 240 original articles in peer-reviewed journals and patents in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and is an honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark.

Mikael Thomsen, PhD
Co-Founder, expert drug developer, seasoned biotech entrepreneur

Dr. Mikael Thomsen has more than 25 years of experience from the pharma and biotech industry and worked within different major pharmaceutical companies including Novartis Pharma, Switzerland, Novo Nordisk, Denmark as well as at the U.S. Food and Drug Administration. He is co-founder of numerous international biotech companies including Contera Pharma. He is an experienced Clinical Pharmacologist and has had roles as Head of Clinical Pharmacology, VP Development, Chief Development Officer and Chief Scientific Officer, where he managed departments organizing all the activities leading a drug from late Discovery trough clinical development. He has been involved in several product filings as well as interactions with authorities from EMA, FDA and MHLW (Japan).

Mikael Thomsen has two M. Sc. degrees (Pharmacy and Human Biology; from University of Pharmaceutical Sciences, Copenhagen and University of Copenhagen, Medical Faculty) and has a PhD in Pharmacology and Toxicology (University of Copenhagen and FDA site, Arkansas, US) and a degree in Pharmaceutical Medicine (ECPM, Basel, Switzerland). He is a member of several pharmaceutical societies and has authored or co-authored more than 50 publications/abstracts related to drug development as well co-author of several patents.

Seong-Beom Koh, MD, PhD
Professor, Korea University, Seoul, South-Korea

Professor, Korea University, Seoul, South-Korea

Professor Seong-Beom Koh, MD, PhD, is a neurologist at Korea University | KU, Department of Neurology, in Seoul. He has contributed significantly to the field of movement disorders, with special focus on Parkinson´s disease, and has authored or co-authored more than 150 publications.

January 2022 ~ today: 9th President of The Korean Movement Disorder Society
September 2006 – August 2007: Research Associate of MRC Clinical Sciences Centre, London, United Kingdom
March 2003 ~ today: Director neurology Korea University Guro Hospital, Seoul, South-Korea
March 2001 – today: Professor (Full), Department of Neurology, Korea University, Seoul, South-Korea

Recent News

September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

South Korea map icon

Contera Pharma Korea

7, SangDo-Ro, Dongjak-Gu
Seoul, 06955
Korea

info@conterapharma.com

Contact us

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

Contera Pharma Korea

7, SangDo-Ro,

Dongjak-Gu

Seoul, 06955

Korea

info@conterapharma.com

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy

Bukwang

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.

Discover Bukwang

Designet af Standoutmedia